Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Boeree

Showing results (91-100 of 123) with videos related to

Pageof 13
Sort By:
International Journal of Antimicrobial Agents|February 16, 2013
Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosisSami O Simons, Jette E Kristiansen, Gyorgy Hajos, et al.
American Journal of Respiratory and Critical Care Medicine|March 26, 2013
Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine modelJurriaan E M de Steenwinkel, Rob E Aarnoutse, Gerjo J de Knegt, et al.
Emerging Infectious Diseases|April 4, 2012
Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TBJurriaan E M de Steenwinkel, Marian T ten Kate, Gerjo J de Knegt, et al.
International Journal of Systematic and Evolutionary Microbiology|March 31, 2009
Mycobacterium noviomagense sp. nov.; clinical relevance evaluated in 17 patientsJakko van Ingen, Martin J Boeree, Wiel C M de Lange, et al.
Plos One|December 14, 2011
SNP/RD typing of Mycobacterium tuberculosis Beijing strains reveals local and worldwide disseminated clonal complexesAnita C Schürch, Kristin Kremer, Amber C A Hendriks, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2014
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populationsRuth Bowness, Martin J Boeree, Rob Aarnoutse, et al.
The European Respiratory Journal|November 3, 2018
Clofazimine does not lead to significant QT interval prolongation: a multicentre studySanne M H Zweijpfenning, Hester van Groningen, Jakko van Ingen, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2012
Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosisJurriaan E M de Steenwinkel, Marian T ten Kate, Gerjo J de Knegt, et al.
The European Respiratory Journal|February 5, 2021
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg<sup>-1</sup> rifampicinLindsey H M Te Brake, Veronique de Jager, Kim Narunsky, et al.
Antiviral Therapy|October 9, 2012
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety studyHadija H Semvua, Charles M Mtabho, Quirine Fillekes, et al.
Pageof 13

Showing results (91-100 of 123) with videos related to

Sort By:
Pageof 13
International Journal of Antimicrobial Agents|February 16, 2013
Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosisSami O Simons, Jette E Kristiansen, Gyorgy Hajos, et al.
American Journal of Respiratory and Critical Care Medicine|March 26, 2013
Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine modelJurriaan E M de Steenwinkel, Rob E Aarnoutse, Gerjo J de Knegt, et al.
Emerging Infectious Diseases|April 4, 2012
Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TBJurriaan E M de Steenwinkel, Marian T ten Kate, Gerjo J de Knegt, et al.
International Journal of Systematic and Evolutionary Microbiology|March 31, 2009
Mycobacterium noviomagense sp. nov.; clinical relevance evaluated in 17 patientsJakko van Ingen, Martin J Boeree, Wiel C M de Lange, et al.
Plos One|December 14, 2011
SNP/RD typing of Mycobacterium tuberculosis Beijing strains reveals local and worldwide disseminated clonal complexesAnita C Schürch, Kristin Kremer, Amber C A Hendriks, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2014
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populationsRuth Bowness, Martin J Boeree, Rob Aarnoutse, et al.
The European Respiratory Journal|November 3, 2018
Clofazimine does not lead to significant QT interval prolongation: a multicentre studySanne M H Zweijpfenning, Hester van Groningen, Jakko van Ingen, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2012
Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosisJurriaan E M de Steenwinkel, Marian T ten Kate, Gerjo J de Knegt, et al.
The European Respiratory Journal|February 5, 2021
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg<sup>-1</sup> rifampicinLindsey H M Te Brake, Veronique de Jager, Kim Narunsky, et al.
Antiviral Therapy|October 9, 2012
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety studyHadija H Semvua, Charles M Mtabho, Quirine Fillekes, et al.
Pageof 13